T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today highlighted four new studies supporting the T2Bacteria® Panel, the T2Candida® Panel and the T2Resistance® Panel that were recently presented at the IDWeek conference in Boston, Massachusetts. The data demonstrates the speed, accuracy and clinical benefits of the T2Dx® Instrument and T2 Biosystems’ sepsis panels and early analytical data on the T2Resistance Panel.
“We are encouraged by our latest clinical results as they showcase the critical detection capabilities of both our instrument and sepsis test panels. Adding to our clinical data library and increasing awareness of the clinical and economic benefits of our technology is an important part of our commercial strategy,” said John Sperzel, Chairman and CEO of T2 Biosystems. “In addition, we appreciate the strong display of support from our customers as they continue to highlight real world performance and benefits of our sepsis products in their sepsis patient management.”
Data Highlights
Acting on Results: How Culture Independent Diagnostics Impact Patient Care and Stewardship
Audry Hawkins, PharmD, BCIDP, University of Louisville (UofL) Health System and Navaneeth Narayanan, PharmD, MPH, BCIDP, Robert Wood Johnson Hospital
Speakers reviewed the implementation of T2Bacteria and T2Candida, clinical impacts and case studies:
- Reviewed patient selection criteria for T2Bacteria at UofL Health System and shared 3 clinical cases where T2Bacteria facilitated faster optimization of antimicrobial therapy and provided clarity in the setting of negative cultures in highly antimicrobial experienced patients.
- Reviewed T2Candida patient criteria and algorithms for responding to T2Candida results at Robert Wood Johnson Hospital and shared 2 clinical cases where T2Candida facilitated appropriate source evaluation and control in a critically ill patient in the setting of a positive result and facilitated de-escalation of antifungals in the setting of a negative result.
Candidemia: Role of T2Candida® compared to Bact/Alert Virtuo blood culture system in a real-world setting
Birk NK et al., Henry Ford Hospital
The poster presentation found that T2Candida continues to outperform at detecting candidemia blood culture even as blood culture monitoring technology advances.
- Retrospective study comparing all patients with T2Candida and blood culture results collected from January 2018 to January 2019 (VersaTREK; n=522) and March 2019 to March 2020 (Virtuo; n=348) comparing the positivity rate of T2Candida and the two respective blood culture monitoring systems. Positivity rates were significantly higher with T2Candida (8.6%) compared to blood culture (2.7%) in the VersaTREK cohort, p<0.001. Positivity rates were significantly higher with T2Candida (9.8%) compared to blood culture (2.3%) in the Virtuo cohort, p<0.001.
Predictors of 30-Day Mortality Among Critically Ill Patients with Candidemia Identified by T2Candida Panel
Caniff KE et al., Anti-infective Research Laboratory/Wayne State University
Poster on retrospective, multi-center study evaluating predictors of 30-day mortality in patients with known T2Candida positive results including the following conclusions:
- “Empiric antifungal administration and ID consultation are modifiable risk factors that were independently associated with reduced odds of 30-day mortality in patients with candidemia identified by T2Candida Panel, highlighting their importance in clinical management”
- “Real-world use of the T2Candida Panel allowed for rapid identification of candidemia and prompt initiation of definitive therapy”
Rapid Detection of Antibiotic Resistance Genes Direct from Whole Blood Samples by T2 Magnetic Resonance (T2MR®)
Wang J et al., T2Biosystems
T2 Biosystems authored poster on analytical studies evaluating the limit of detection, analytical reactivity/inclusivity, interfering substances, and analytical specificity/exclusivity of the T2Resistance Panel.
- Limit of detection for all 13 genes was <20 CFU/mL (ranging from 3-18 CFU/mL).
- The panel has broad inclusivity of resistance gene variants, no observed interfering substances from those tested, and no observed cross-reactivity with other species or resistance markers.
